Literature DB >> 9607853

Spontaneous loss of viral episomes accompanying Epstein-Barr virus reactivation in a Burkitt's lymphoma cell line.

S K Srinivas1, J T Sample, J W Sixbey.   

Abstract

Life-long viral persistence is a hallmark of human herpesvirus infection. In the Epstein-Barr virus (EBV)-positive Burkitt's lymphoma (BL) cell line, Mutu, spontaneous loss of all viral episomes accompanied productive viral DNA replication. The molecular configuration of intracellular EBV DNA evolved from monoclonal episomes in cells retaining the original tumor phenotype to predominantly replicating linear DNA and, subsequently, only integrated forms in BL cells that had acquired the lymphoblastoid cell phenotype. Transient appearance of deleted, rearranged WZhet EBV DNA capable of disrupting viral latency, along with the integration of viral DNA into human chromosomes, indicates a genetic instability in the host cell which, if duplicated in vivo, may affect configuration and persistence of the viral genome in expanding malignant cell clones.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607853     DOI: 10.1086/517427

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells : no evidence for the persistence of integrated viral fragments inLatent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease.

Authors:  A Staratschek-Jox; S Kotkowski; G Belge; T Rüdiger; J Bullerdiek; V Diehl; J Wolf
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 3.  Gammaherpesviruses and "Hit-and-Run" oncogenesis.

Authors:  R F Ambinder
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors:  Ning Li; Scott Thompson; Hualiang Jiang; Paul M Lieberman; Cheng Luo
Journal:  Expert Opin Drug Discov       Date:  2010-12       Impact factor: 6.098

5.  The tumor virus landscape of AIDS-related lymphomas.

Authors:  Aaron Arvey; Akinyemi I Ojesina; Chandra Sekhar Pedamallu; Gianna Ballon; Joonil Jung; Fujiko Duke; Lorenzo Leoncini; Giulia De Falco; Eric Bressman; Wayne Tam; Amy Chadburn; Matthew Meyerson; Ethel Cesarman
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

6.  Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.

Authors:  P Trivedi; P Spinsanti; L Cuomo; M Volpe; K Takada; L Frati; A Faggioni
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma.

Authors:  Lynn I Levin; Ellen T Chang; Richard F Ambinder; Evelyne T Lennette; Mark V Rubertone; Risa B Mann; Michael Borowitz; Edward G Weir; Susan L Abbondanzo; Nancy E Mueller
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

8.  Epstein-Barr virus episome stability is coupled to a delay in replication timing.

Authors:  Jing Zhou; Andrew R Snyder; Paul M Lieberman
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Complex genomic rearrangement of ALK loci associated with integrated human Epstein-Barr virus in a post-transplant myogenic liver tumor.

Authors:  Maria Debiec-Rychter; Romaric Croes; Rita De Vos; Peter Marynen; Tania Roskams; Anne Hagemeijer; Rita Lombaerts; Raf Sciot
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Multiple pathways for Epstein-Barr virus episome loss from nasopharyngeal carcinoma.

Authors:  Dirk P Dittmer; Chelsey J Hilscher; Margaret L Gulley; Eric V Yang; Min Chen; Ronald Glaser
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.